The correlation between CYP2C19 Polymorphisms and recurrent risk in Patients with Ischemic Stroke treated with Clopidogrel in Kurdistan region-Iraq
DOI:
https://doi.org/10.31351/vol31iss2pp251-259Keywords:
CYP2C19, gene polymorphism, clopidogrel, stroke.Abstract
Clopidogrel is a prodrug that must be transformed into an active metabolite by hepatic cytochrome P450 (CYP) isoenzymes to prevent platelet clotting. Polymorphisms of the CYP2C19 gene can cause a reduction or complete loss of CYP2C19 enzyme activity resulting in inhibiting clopidogrel metabolism, effectiveness and increase stroke recurrence risk in ischemic stroke patients. This study aims to investigate the correlation between genetic polymorphisms in CYP2C19*2 and*3 and recurrent risk in patients with ischemic stroke taking clopidogrel 75mg in Kurdistan region –Iraq. This retrospective case-control study was carried out at Kurdistan, Erbil, Medicina medical center, and Rizgary general hospital from January 2021 to August 2021. The blood sample was taken from the participants and tested for genotyping. The collection of data was taken from patients' medical charts in the hospital and patients’ electronic medical records from the neurology clinic. Sixty patients participated, (34) were male and (26) were female, with age range (38-96) years, diagnosed from not more than two years with ischemic stroke and taking 75 mg clopidogrel maintenance dose. Genotyping analysis showed 61.7 % were homozygotes for wild allele *1, the heterozygotes divided into 26.7% (*1/*2) and 6.7 % (*1/*3) genotype, while the homozygotes for mutant alleles CYP2C19*2,*3 distributed in 3.3 %(*2/*2) and 1.7 %(*3/*3). The (*2/*3) was not detected in the study population. A significant relation was found between risk of stroke recurrence with carrying the variant allele CYP2C19 *2, reduced CYP2C19 enzyme metabolic activity, and ACEIs/ARBs usage (P = 0.024, P = 0.039, P=0.24 respectively). On the other hand, there was no significant relationship between the risk of stroke recurrence and carrying the variant allele CYP2C19 *3 (P = 1.000). Ischemic stroke patients treated with clopidogrel and carrying a CYP2C19*2 allele had a higher risk of recurrent stroke as it is associated with reduced the metabolic activity of CYP2C19 enzyme leading to reduction of clopidogrel effect.
References
ischemic stroke. BMJ. 2020;368.
Cavallari LH, Momary KM. Pharmacogenetics in Cardiovascular Diseases. Pharmacogenomics. 2019. 133–179 p.
Catanese L, Tarsia J, Fisher M. Acute Ischemic Stroke Therapy Overview. Circ Res. 2017;120(3):541–58.
Oza R, Rundell K, Garcellano M. Recurrent Ischemic Stroke: Strategies for Prevention. Am Fam Physician. 2017;96(7):436–40.
Campbell BCV, De Silva DA, Macleod MR, Coutts SB, Schwamm LH, Davis SM, et al. Ischaemic stroke. Nat Rev Dis Prim [Internet]. 2019;5(1). Available from: http://dx.doi.org/10.1038/s41572-019-0118-8
Schneider S, Kornejeva A, Vibo R, Kõrv J. Risk Factors and Etiology of Young Ischemic Stroke Patients in Estonia. Stroke Res Treat. 2017;2017.
Hackam DG, Spence JD. Antiplatelet therapy in ischemic stroke and transient ischemic attack: An overview of major trials and meta-analyses. Stroke. 2019;50(3):773–8.
Borghol A, Onor I, Neuliep A, Zaki A, Andonie G, Zaki A, et al. Effectiveness of mono antiplatelet therapy vs dual antiplatelet therapy in ischemic stroke or transient ischemic attack—Special subgroup consideration for the African-American Population. Int J Clin Pract. 2020;74(7).
Hong KS, Lee SH, Kim EG, Cho KH, Chang D Il, Rha JH, et al. Recurrent Ischemic Lesions after Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. Stroke. 2016;47(9):2323–30.
Jiang XL, Samant S, Lesko LJ, Schmidt S. Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. Clin Pharmacokinet. 2015;54(2):147–66.
Li C, Jia W, Li J, Li F, Ma J, Zhou L. Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients. BMC Neurol. 2021;21(1):1–7.
Golukhova EZ, Ryabinina MN, Bulaeva NI, Grigorian M V., Kubova MC, Serebruany VL. Clopidogrel response variability: Impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting. Am J Ther. 2015;22(3):222–30.
Jabir FA, Hoidy WH. Pharmacogenetics as Personalized Medicine: Association Investigation of SOD2 rs4880, CYP2C19 rs4244285, and FCGR2A rs1801274 Polymorphisms in a Breast Cancer Population in Iraqi Women. Clin Breast Cancer [Internet]. 2018;18(5):e863–8. Available from: http://dx.doi.org/10.1016/j.clbc.2018.01.009
Vidyanti AN, Chan L, Lin CL, Muo CH, Hsu CY, Chen YC, et al. Erratum: Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study (PLoS ONE (2019) 14: 8 (e0221750) DOI: 10.1371/journal.pone.0221750). PLoS One. 2020;15(4):1–10.
Alhazzani AA, Munisamy M, Karunakaran G. Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia. Neurosciences. 2017;22(1):31–7.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
This work is licensed under a Creative Commons Attribution 4.0 International License.
